Back to Authors

Hill, Brian T.

https://orcid.org/0000-0001-8781-3327

Mayo Clinic

Cleveland Clinic

Citations 87

Outcomes of DLBCL Patients Achieving Complete Remission after R-ICE Chemoimmunotherapy
Auberle, Christine , Goparaju, Krishna, Baidoun, Firas, Cashen, Amanda F. , Hill, Brian T. , Caimi, Paolo F. , Baidoun, Firas

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 381-383

10.1182/blood-2022-170752 Get It

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hill, Brian T. , Maris, Michael, Byrne, Michael , Pagel, John M. , Zheng, Yan , Kanska, Justyna, Zhang, Wangshu , Masouleh, Behzad Kharabi, Granados, Enrique , Ibarz, Javier Pinilla, Davids, Matthew S. , Kenderian, Saad S. , Flinn, Ian W. , Ghia, Paolo , Bartlett, Nancy L.

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7454-7456

10.1182/blood-2022-167868 Get It

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
Khurana, Arushi , Bailey, Megumi, Bansal, Radhika , Hunter, Bradley D. , Lunning, Matthew A. , Dahiya, Saurabh , Hill, Brian T. , Patel, Krish , Oluwole, Olalekan O. , Lin, Yi , Oluwole, Olalekan O , Patel, Krish , Iqbal, Madiha , Lee, Catherine J , Jaglowski, Samantha , Jain, Michael D. , Bachanová, Veronika , Farooq, Umar , Ahmed, Sairah , Muñoz, Javier

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4657-4660

10.1182/blood-2022-170486 Get It

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
Lunning, Matthew A. , Wang, Hailin , Hu, Zhen‐Huan , Jacobson, Caron A. , Lin, Yi , Hill, Brian T. , Neelapu, Sattva S. , Miao, Harry , Shahani, Shilpa, Patel, Anik R. , Spooner, Clare, Fu, Christine, Xu, Hairong, Pasquini, Marcelo C. , Locke, Frederick L. , Siddiqi, Tanya , Ahmed, Sairah , Miklos, David B. , Ghobadi, Armin , Westin, Jason R.

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1852-1855

10.1182/blood-2022-162421 Get It

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
Hu, Zhen‐Huan , Jacobson, Caron A. , Nikiforow, Sarah , Lin, Yi , Lunning, Matthew A. , Hill, Brian T. , Miao, Harry , Shahani, Shilpa, Spooner, Clare, Fu, Christine, Patel, Anik R. , Xu, Hairong, Pasquini, Marcelo C. , Locke, Frederick L. , Siddiqi, Tanya , Ahmed, Sairah , Miklos, David B. , Ghobadi, Armin

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7512-7515

10.1182/blood-2022-155603 Get It

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology
Ciuro, Jordan , Henry, Elizabeth , Housri, Nadine , Brém, Elizabeth , Brooks, Taylor , Derman, Ben A, Hill, Brian T. , Lunning, Matthew A. , Rutherford, Sarah C. , Zanwar, Saurabh , Lee, Lauren E. , Brooks, Taylor R , Banerjee, Rahul , Hofmeister, Craig C. , Matasar, Matthew J. , Phillips, Tycel

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 13180-13181

10.1182/blood-2022-167959 Get It

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
Wierda, William G. , Brown, Jennifer R. , Bilgrami, S, Bociek, Greg, Brander, Danielle M. , Chanan‐Khan, Asher , Davis, Randall S. , Eradat, Herbert, Fletcher, Christopher D.�M. , Gaballa, Sameh , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Hill, Brian T. , Kaesberg, Paul, Kaplan, Lawrence D. , Ma, Shuo , Mato, Anthony, Mosse, Claudio A. , Stephens, Deborah M. , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Woyach, Jennifer A. , Ye, J Christine, Dwyer, Mary A., Sundar, Hema, Chanan-Khan, Asher A., Stephens, Deborah M , Ma, Shuo , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Coutré, Steven , Ghobadi, Armin , Kamdar, Manali , Khan, Nadia , Kipps, Thomas J. , Schuster, Stephen J. , Siddiqi, Tanya

Journal of the National Comprehensive Cancer Network | June 17, 2022 | Volume: 20 | Issue: 6 | Pages: 622-634

10.6004/jnccn.2022.0031 Get It

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.